Hormonal treatment alone for locally advanced prostate cancer

BJU International, Supplement

Volumn 94, Issue 3, 2004, Pages 14-15

  Mottet, N ^a  

^a Clinique Mutualiste   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ASTHENIA; CANCER HORMONE THERAPY; CANCER RISK; CASTRATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DEPRESSION; FATIGUE; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO; LIBIDO DISORDER; MASTALGIA; MONOTHERAPY; ORCHIECTOMY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 11144221991     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation use for newly diagnosed prostate cancer. Urology 2002; 60: 7-11
2. Harlan LC, Potosky A, Gilliland FD et al. Factors associated with initial therapy for clinically localized prostate cancer. J Natl Cancer Inst 2001; 93: 1864-71
3. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988; 7: 165-70
4. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79: 235-46
5. Schröder FH, Kurth KH, Fossa SD et al. Early versus delayed endocrine treatment in pN1-3M0 prostate cancer without local treatment of the primary tumor. Results of EORTC 30846 - a phase III study. J Urol 2003; 169: 398 (Abstract 1487)
6. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8
7. Soloway MS. Timing of androgen deprivation for prostate cancer: benefits versus side effects - a patient-physician dialogue. Urology 2002; 60: 735-7
8. Waltregny D, Boca P, Nicolas H et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a randomized prospective multicenter clinical trial. J Urol 2002; 167: 175
9. Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 2000; 5: 45-52
10. Theyer G, Ulsperger E, Baumgartner G, Raderer M, Hamilton G. Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patients. Ann Oncol 2000; 11: 877-81
11. Albrecht W, Collette L, Fava C et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003; 44: 505-11
12. Bouchot O, Lenormand L, Karam G et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000; 38: 543-9
13. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 47-54
14. Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000; 164: 1579-82
15. Boccardo F, Barichello M, Battaglia M et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 2002; 42: 481-90